Vincerx Pharma, Inc.
Every calculator, already run for VINC
Open the full toolkit →You have the numbers on VINC. Get the argument.
A written report on which of these readings actually decide the outcome for Vincerx Pharma, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Ownership & short interest
Insider Trading Activity for VINC
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Vincerx Pharma, Inc.
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and provides CellTrapper technology for use in reduction of payload cellular permeability. The company develops VIP943, an antibody drug conjugate in Phase 1 dose-escalation study for relapsed/refractory acute myeloid leukemia, higher-risk MDS, and B-cell acute lymphoblastic leukemia; VIP236, an SMDC, which…
VINC — frequently asked
Is VINC a buy right now?
Wall Street's consensus rating on Vincerx Pharma, Inc. is none. Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Compare Vincerx Pharma, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Vincerx Pharma, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full VINC research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Vincerx Pharma, Inc., in minutes. 3 free reports included with every account — no credit card required.